Next Article in Journal / Special Issue
S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction
Previous Article in Journal
Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer
Previous Article in Special Issue
Control of Wnt Receptor Turnover by R-spondin-ZNRF3/RNF43 Signaling Module and Its Dysregulation in Cancer

Wnt Signaling in Renal Cell Carcinoma

Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, Oulu Center for Cell Matrix Research, University of Oulu, P.O.Box 5000, FI-90014 Oulu, Finland
Author to whom correspondence should be addressed.
Academic Editors: Renée van Amerongen and Walter Birchmeier
Cancers 2016, 8(6), 57;
Received: 31 March 2016 / Revised: 31 May 2016 / Accepted: 12 June 2016 / Published: 17 June 2016
(This article belongs to the Special Issue Wnt Signaling in Cancer)
Renal cell carcinoma (RCC) accounts for 90% of all kidney cancers. Due to poor diagnosis, high resistance to the systemic therapies and the fact that most RCC cases occur sporadically, current research switched its focus on studying the molecular mechanisms underlying RCC. The aim is the discovery of new effective and less toxic anti-cancer drugs and novel diagnostic markers. Besides the PI3K/Akt/mTOR, HGF/Met and VHL/hypoxia cellular signaling pathways, the involvement of the Wnt/β-catenin pathway in RCC is commonly studied. Wnt signaling and its targeted genes are known to actively participate in different biological processes during embryonic development and renal cancer. Recently, studies have shown that targeting this pathway by alternating/inhibiting its intracellular signal transduction can reduce cancer cells viability and inhibit their growth. The targets and drugs identified show promising potential to serve as novel RCC therapeutics and prognostic markers. This review aims to summarize the current status quo regarding recent research on RCC focusing on the involvement of the Wnt/β-catenin pathway and how its understanding could facilitate the identification of potential therapeutic targets, new drugs and diagnostic biomarkers. View Full-Text
Keywords: renal cell carcinoma; Wnt signaling pathway; therapeutic target; development renal cell carcinoma; Wnt signaling pathway; therapeutic target; development
Show Figures

Figure 1

MDPI and ACS Style

Xu, Q.; Krause, M.; Samoylenko, A.; Vainio, S. Wnt Signaling in Renal Cell Carcinoma. Cancers 2016, 8, 57.

AMA Style

Xu Q, Krause M, Samoylenko A, Vainio S. Wnt Signaling in Renal Cell Carcinoma. Cancers. 2016; 8(6):57.

Chicago/Turabian Style

Xu, Qi, Mirja Krause, Anatoly Samoylenko, and Seppo Vainio. 2016. "Wnt Signaling in Renal Cell Carcinoma" Cancers 8, no. 6: 57.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop